Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children

The article analyzes the current data on the pathogenesis of atopic dermatitis. It discusses the role of the damaged dermal barrier structure in the development of food allergies and presents the results confirming the theory of transdermal sensibilisation to allergens in addition to hereditary and...

Full description

Saved in:
Bibliographic Details
Main Authors: Nikolay N. Murashkin, Alexander I. Materikin, Eduard T. Ambarchyan, Roman V. Epishev
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2016-12-01
Series:Вопросы современной педиатрии
Subjects:
Online Access:https://vsp.spr-journal.ru/jour/article/view/1696
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849690705872551936
author Nikolay N. Murashkin
Alexander I. Materikin
Eduard T. Ambarchyan
Roman V. Epishev
author_facet Nikolay N. Murashkin
Alexander I. Materikin
Eduard T. Ambarchyan
Roman V. Epishev
author_sort Nikolay N. Murashkin
collection DOAJ
description The article analyzes the current data on the pathogenesis of atopic dermatitis. It discusses the role of the damaged dermal barrier structure in the development of food allergies and presents the results confirming the theory of transdermal sensibilisation to allergens in addition to hereditary and exogenous factors. Current local treatment of atopic dermatitis using topical glucocorticosteroids (tGCs) aimed at reducing the severity of symptoms is often associated with the risk of complications. The data on the effective use of topical calcineurin inhibitors (TCI) to eliminate the side effects of tGCs are presented. The results of the possible use of pimecrolimus in the form of 1% cream for gradual withdrawal of tGCs in the long-term use are shown. The data of reviews and meta-analyses for the last decade are given showing that there is no evidence that the use of TIC is associated with an increased risk of lymphoma. The authors conclude that pimecrolimus in the form of 1% cream is the best medication for topical therapy in children with mild and moderate form of the disease. It is also considered the best preparation for the proactive treatment of atopic dermatitis in the long period of time in order to prevent recurrences.
format Article
id doaj-art-355406d783fa40ce9264f2fc6f7afdb7
institution DOAJ
issn 1682-5527
1682-5535
language English
publishDate 2016-12-01
publisher "Paediatrician" Publishers LLC
record_format Article
series Вопросы современной педиатрии
spelling doaj-art-355406d783fa40ce9264f2fc6f7afdb72025-08-20T03:21:13Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352016-12-0115658458910.15690/vsp.v15i6.16551645Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in ChildrenNikolay N. Murashkin0Alexander I. Materikin1Eduard T. Ambarchyan2Roman V. Epishev3Scientific Center of Children’s Health Sechenov First Moscow State Medical UniversityScientific Center of Children’s HealthScientific Center of Children’s HealthScientific Center of Children’s HealthThe article analyzes the current data on the pathogenesis of atopic dermatitis. It discusses the role of the damaged dermal barrier structure in the development of food allergies and presents the results confirming the theory of transdermal sensibilisation to allergens in addition to hereditary and exogenous factors. Current local treatment of atopic dermatitis using topical glucocorticosteroids (tGCs) aimed at reducing the severity of symptoms is often associated with the risk of complications. The data on the effective use of topical calcineurin inhibitors (TCI) to eliminate the side effects of tGCs are presented. The results of the possible use of pimecrolimus in the form of 1% cream for gradual withdrawal of tGCs in the long-term use are shown. The data of reviews and meta-analyses for the last decade are given showing that there is no evidence that the use of TIC is associated with an increased risk of lymphoma. The authors conclude that pimecrolimus in the form of 1% cream is the best medication for topical therapy in children with mild and moderate form of the disease. It is also considered the best preparation for the proactive treatment of atopic dermatitis in the long period of time in order to prevent recurrences.https://vsp.spr-journal.ru/jour/article/view/1696atopic dermatitischildrenpimecrolimus
spellingShingle Nikolay N. Murashkin
Alexander I. Materikin
Eduard T. Ambarchyan
Roman V. Epishev
Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children
Вопросы современной педиатрии
atopic dermatitis
children
pimecrolimus
title Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children
title_full Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children
title_fullStr Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children
title_full_unstemmed Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children
title_short Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children
title_sort current views on the pathogenesis and principles of external treatment of atopic dermatitis in children
topic atopic dermatitis
children
pimecrolimus
url https://vsp.spr-journal.ru/jour/article/view/1696
work_keys_str_mv AT nikolaynmurashkin currentviewsonthepathogenesisandprinciplesofexternaltreatmentofatopicdermatitisinchildren
AT alexanderimaterikin currentviewsonthepathogenesisandprinciplesofexternaltreatmentofatopicdermatitisinchildren
AT eduardtambarchyan currentviewsonthepathogenesisandprinciplesofexternaltreatmentofatopicdermatitisinchildren
AT romanvepishev currentviewsonthepathogenesisandprinciplesofexternaltreatmentofatopicdermatitisinchildren